Ning Wang
Eli Lilly and Company
5 Papers
Ning Wang is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Poloxamer & Chemistry. The author has an hindex of 4, co-authored 5 publications. Previous affiliations of Ning Wang include University of Michigan.
Chat about Author
Papers
A Novel Sample Preparation for Shotgun Proteomics Characterization of HCPs in Antibodies.
Lihua Huang,Ning Wang,Charles E. Mitchell,Tammy J. Brownlee,Steven R. Maple,Michael R. De Felippis +5 more
TL;DR: Application of this method to analyze a high-purity NIST monoclonal antibody standard RM 8670 derived from a murine cell line expression system resulted in detection of 60 mouse HCPs; twice as many as previously reported with 2D-UPLC/IM/MSE method.
90
Negative-ion electron capture dissociation: radical-driven fragmentation of charge-increased gaseous peptide anions.
TL;DR: It is found that peptide anions can capture electrons within a rather narrow energy range, resulting in charge-increased radical intermediates that undergo dissociation analogous to that in ECD/ETD.
72
Solution Stability of Poloxamer 188 Under Stress Conditions.
Tingting Wang,Markham Aaron Paul,Steven J. Thomas,Ning Wang,Lihua Huang,Matthew Clemens,Natarajan Rajagopalan +6 more
TL;DR: The solution state stability of P188 is evaluated and it is reported that in histidine buffer, oxidation of both P188 and histidine may occur at pharmaceutically relevant conditions.
46
Characterization of Synthetic Peptide Therapeutics Using Liquid Chromatography-Mass Spectrometry: Challenges, Solutions, Pitfalls, and Future Perspectives.
TL;DR: In this article, an overview of impurities in synthetic peptide therapeutics is provided in the context of how the knowledge from detailed characterization of the impurities using liquid chromatography-mass spectrometry (LC-MS) can be used to develop the manufacturing process and control strategy for synthetic peptides following the critical quality attribute (CQA)-driven and risk-based approach.
10
Hydrogen/deuterium exchange-mass spectrometry analysis of high concentration biotherapeutics: application to phase-separated antibody formulations.
TL;DR: A novel dilution-free hydrogen/deuterium exchange (HDX) mass spectrometry (MS) method is developed for the direct conformational analysis of high concentration biotherapeutics that can potentially provide useful insights into the unusual behavior of therapeutic proteins in high concentration formulations, aiding their development.
9